OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentAetnaPolicy 0524

Zoledronic Acid

Customize your policy alerts

Sign up for Aetna Policy 0524 alerts

Get alerted when Policy 0524 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Coverage and medical necessity criteria for zoledronic acid injections (4 mg and 5 mg formulations) for members under Aetna commercial medical plans; includes indications, continuation criteria, dosing, and coding guidance. Medicare Part B has separate criteria.

Policy Summary

PayerAetna

PolicyZoledronic Acid

Policy CodePolicy 0524

Change TypeNo material changes

Effective DateMar 12, 2002

Last ReviewFeb 1, 2024

Next Review DateDec 12, 2024

Key ActionObtain prior authorization (HCPCS J3489) and document indication, baseline renal function, and relevant lab values before zoledronic acid administration.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

5 mgdose for osteoporosis (Reclast)

4 mgdose for malignancy / bone metastases

<35 mL/minReclast contraindication CrCl

>=24 mocontinuation reference duration

70%vertebral fracture RRR (HORIZON)

>=12 mg/dLalbumin-corrected calcium threshold

Coverage and Medical Necessity Criteria

Covered Indications and Evidence

Covered when ALL of the following general conditions are met unless a more specific criteria group below applies:

ALL of the following

Requested agent is zoledronic acid (4 mg or 5 mg) for an indication listed in this policy or an FDA-approved/compendial indication.
For zoledronic acid 5 mg (Reclast) use, member meets specific initial or continuation criteria for osteoporosis, Paget’s disease, or glucocorticoid-induced osteoporosis as described in the respective criteria groups below.
For zoledronic acid 4 mg use, member meets specific initial or continuation criteria for oncology-related bone disease, hypercalcemia of malignancy, or other compendial indications listed in this policy.
Baseline and ongoing monitoring and precautions are documented (e.g., serum creatinine/CrCl assessment prior to dosing, corrected serum calcium, dental evaluation when indicated, and supplementation of calcium and vitamin D as clinically appropriate).
Operational: Verify most recent labs and dental/medical notes in prior authorization documentation.

Zoledronic acid 5 mg - Continuation

Continuation of therapy for zoledronic acid 5 mg is considered medically necessary when ONE of the following is met:

ANY of the following

Member has Paget’s disease of bone and continues to meet all initial selection criteria (including documented clinical benefit or indication for continued treatment).
Member is currently receiving zoledronic acid 5 mg through a previously authorized benefit and meets either: (1) received less than 24 months of therapy without clinically significant adverse events; OR (2) received ≥24 months of therapy and demonstrates clinical benefit (improvement or stabilization in T-score since previous bone mass measurement) and has not experienced treatment-related adverse effects.
Operational: prior authorization should include prior treatment dates, bone density comparison, and adverse event documentation.

Zoledronic acid 5 mg - Initial Approval

Initial approval for zoledronic acid 5 mg (Reclast) is considered medically necessary for the following indications when criteria shown for each condition are met:

paragraphs:[

Zoledronic acid 4 mg - Initial Approval

Initial approval for zoledronic acid 4 mg is considered medically necessary for the following indications when criteria shown for each condition are met:

ANY of the following

Bone metastases from a solid tumor
- Documented bone metastases from a solid tumor (e.g., breast, non-small cell lung, thyroid, renal, prostate).
- Use is for treatment or prevention of skeletal-related events in conjunction with standard antineoplastic therapy as appropriate.
Multiple Myeloma
- Diagnosis of multiple myeloma with bone disease and use is for treatment or prevention of skeletal-related events in conjunction with standard antineoplastic therapy.
Hypercalcemia of Malignancy

Covered indications / evidence-based rationale

Examples of trial-based and guideline-supported indications (evidence-based rationale):

ANY of the following

Bone-modifying therapy for patients with bone metastases from solid tumors: ASCO recommends zoledronic acid 4 mg IV every 3–4 weeks or other bone-modifying agents to reduce skeletal-related events; dosing and renal monitoring per label.
Multiple myeloma with bone disease: randomized trials show zoledronic acid reduces SREs and is an appropriate bone-modifying agent in conjunction with antineoplastic therapy.
Postmenopausal women with early breast cancer: meta-analyses (EBCTCG and others) demonstrate benefit of adjuvant bisphosphonates in reducing bone recurrence and breast cancer mortality primarily in postmenopausal women; guideline guidance supports consideration of zoledronic acid for postmenopausal patients receiving adjuvant systemic therapy.
Hypercalcemia of malignancy: randomized trials presented to FDA demonstrate faster and higher rates of calcium normalization with zoledronic acid 4 mg compared with pamidronate.

Limited / Investigational Indications

The following indications are considered limited evidence or investigational and are not routinely covered due to insufficient or low-quality evidence:

ANY of the following

Gorham-Stout disease (disappearing bone disease) — evidence limited to case reports and small series; use may be considered only in exceptional circumstances with specialty consultation and documentation of lack of alternatives.
Osteogenesis imperfecta — intravenous bisphosphonates (e.g., pamidronate) are standard in children; zoledronic acid evidence is limited and remains investigational for routine use outside trial settings or specialty protocols.
Mastocytosis-related osteoporosis — small studies suggest benefit in BMD, but larger confirmatory data are limited; consider on case-by-case basis with specialty documentation.
Prevention of insufficiency fractures and avascular necrosis related to pelvic radiotherapy — RCT evidence is very low certainty and does not support routine use; consider only in the context of clinical trials.

Coding and Clinical Thresholds

Covered/related HCPCS/CPT codesmixed

96365-96368	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug).
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular.
96379	Unlisted therapeutic, prophylactic, or diagnostic intravenous or intra-arterial injection or infusion.
J3489	Injection, zoledronic acid, 1 mg.
J1436	Injection, etidronate disodium, per 300 mg.
J1740	Injection, ibandronate sodium, 1 mg.
J2430	Injection, pamidronate disodium, per 30 mg.
S0187	Tamoxifen citrate, oral, 10 mg.

Covered ICD-10 codes (selected)ICD-10Covered

M80.00x+ - M81.8	Osteoporosis [see criteria for treatment in men vs. women; not covered for mastocytosis-related osteoporosis].
M88.0 - M88.9	Osteitis deformans [Paget's disease of bone].
E83.52	Hypercalcemia [covered when due to malignancy only].
Q78.1	Polyostotic fibrous dysplasia.
Z79.52	Long term (current) use of systemic steroids.
Z79.811	Long term (current) use of aromatase inhibitors.

ICD-10 codes listed as not covered for CPB indications (selected)ICD-10Not Covered

A52.16	Charcot's arthropathy (tabetic) - listed as not covered
C18.0 - C18.9	Malignant neoplasm of colon - not covered for adjuvant/neoadjuvant
C45.0	Mesothelioma of pleura - not covered
E21.0 - E21.3	Hyperparathyroidism - not covered
F50.0	Anorexia nervosa - not covered

ICD-10 codes appearing in documentICD-10

E21.0 - E21.3	Hyperparathyroidism
E58	Dietary calcium deficiency
E83.51	Hypocalcemia
E83.52	Hypercalcemia [covered when due to malignancy only]
F50.0	Anorexia nervosa
H80.00 - H80.93	Otosclerosis
I35.0	Nonrheumatic aortic (valve) stenosis
J84.81	Lymphangiomatosis
K90.0	Celiac disease [to increase bone mineral density]
L40.50 - L40.59	Arthropathic psoriasis

1–10 of 24

1/3

Covered HCPCS (example from oncology use)HCPCSCovered

J3487

Injection, zoledronic acid, 1 mg

Described drug dosing (clinical trial dosing)mixed

5 mg	Zoledronic acid single IV dose used in trials (administered annually over at least 15 minutes).

T-score thresholds for osteoporosis/osteopenia

Osteoporosis (WHO)T-score less than or equal to -2.5 defines osteoporosis (spine, hip, or forearm)

OsteopeniaPre-treatment T-score greater than -2.5 and less than -1.0

Use in treatment criteriaReclast (5 mg) indicated for treatment/prevention when history of fragility fracture OR pre-treatment T-score ≤ -2.5 OR osteopenia with high FRAX (per appendix)

Creatinine clearance — monitoring and Paget's contraindication note

Creatinine clearance contraindication (Paget/Reclast)Zoledronic acid 5 mg is contraindicated in persons with creatinine clearance < 35 mL/min and in those with evidence of acute renal impairment

Authorization, Documentation, and Clinical Operations

Prior Authorization

Indication-specific authorization

Prior authorization: distinguish formulation and indication during request. Indication-specific authorization is required — document whether the request is for zoledronic acid 5 mg (Reclast) or 4 mg (Zometa/generic) and the covered indication (e.g., postmenopausal osteoporosis, osteoporosis in men, glucocorticoid‑induced osteoporosis, Paget’s disease for 5 mg; bone metastases, hypercalcemia of malignancy, multiple myeloma, ADT‑associated osteoporosis, Langerhans cell histiocytosis, systemic mastocytosis for 4 mg). PA requests should specify dose (4 mg vs 5 mg) since approved uses and dosing/retreatment intervals differ by formulation.

Ensure the requested HCPCS (e.g., J3489) and dose/unit match the indication.
For Paget’s disease include documentation of serum alkaline phosphatase ≥2x age‑adjusted ULN or symptomatic disease.

Documentation Required

Indication and menopausal‑status requirement

When adjuvant or oncology‑adjacent uses are requested (for example, adjuvant therapy in breast cancer or prevention of AI‑associated bone loss), document menopausal status where relevant. Postmenopausal status must be clearly stated; if menopause is surgically or medically induced, document timing and labs (LH, FSH, estradiol) as noted in specialty guidance.

Clinical Background and Evidence Summary

Zoledronic acid is available in intravenous formulations (5 mg, marketed as Reclast for osteoporosis/Paget disease, and 4 mg, formerly Zometa for oncology indications). The 5‑mg Reclast formulation carries labeled renal contraindications and detailed monitoring recommendations; the FDA communicated an updated warning and contraindication related to kidney impairment for Reclast, and clinicians should follow the product label and FDA safety communication.

The policy summarizes trial and guideline evidence supporting ZA for oncology‑related bone disease and adjuvant breast cancer in selected patients. ASCO and Cochrane reviews support ZA (4 mg) for prevention and treatment of skeletal‑related events in patients with bone metastases and multiple myeloma; adjuvant bisphosphonate meta‑analyses show benefit primarily in women who were postmenopausal at treatment initiation, while the AZURE randomized trial did not demonstrate benefit overall and raised safety concerns.

Key trial‑based evidence summarized in the policy includes pooled trials of zoledronic acid versus pamidronate for hypercalcemia of malignancy showing faster normalization of corrected calcium with ZA, a phase III trial demonstrating ZA and pamidronate equivalence for preventing skeletal‑related events in cancer patients with bone metastases, and the HORIZON fracture trials showing that annual 5‑mg ZA reduced vertebral and hip fractures in postmenopausal osteoporosis (trial durations and outcomes are specified elsewhere in the policy). These trial summaries provide the evidence rationale for covered oncology and osteoporosis indications.

For indications with limited evidence, the policy documents small case series and pilot studies—for example, reports of zoledronic acid use in Gorham‑Stout disease, mastocytosis‑related osteoporosis, osteogenesis imperfecta (emerging trials), and a small RCT for chronic low back pain with Modic changes. These data are preliminary or observational and are described as insufficient to establish routine clinical use.

Definitions and Clinical Thresholds

Osteoporosis / Osteopenia — WHO T-score definitions

WHO T-score definitionsOsteoporosis: T-score ≤ -2.5; Osteopenia: T-score between -2.5 and -1.0

ApplicationUsed to determine eligibility for Reclast (5 mg) for postmenopausal women and men with osteoporosis per policy criteria

Clinical noteT-score thresholds are part of initial approval nodes (history of fragility fracture, T-score ≤ -2.5, or osteopenia with high FRAX)

Albumin-corrected calcium (cCa) formula and hypercalcemia definition

cCa calculation (formula)cCa (mg/dL) = Ca (mg/dL) + 0.8 × (4.0 g/dL - patient albumin [g/dL])

Hypercalcemia numeric definitionHypercalcemia of malignancy defined as albumin-corrected calcium ≥ 12 mg/dL [3.0 mmol/L] for 4 mg indication

Policy History and Review Dates

2002-03-12policy_effective

Policy originally became effective on 2002-03-12.

2011-09-01safety_communication_cited

FDA drug safety communication adding a contraindication and updated warning on kidney impairment for Reclast (zoledronic acid) is cited in the policy references.

2024-02-01policy_reviewLatest

Policy Summary

PayerAetna

PolicyZoledronic Acid

Policy CodePolicy 0524

Change TypeNo material changes

Effective DateMar 12, 2002

Last ReviewFeb 1, 2024

Next Review DateDec 12, 2024

Key ActionObtain prior authorization (HCPCS J3489) and document indication, baseline renal function, and relevant lab values before zoledronic acid administration.

SourceLink

On This Page

Documented hypercalcemia of malignancy (albumin-corrected calcium ≥ 12 mg/dL [3.0 mmol/L]) using the standard correction formula;

Other causes of hypercalcemia have been evaluated and managed as appropriate, and patient has been adequately rehydrated and electrolytes monitored per label guidance.

Breast Cancer - Adjuvant use

Postmenopausal (natural or induced by ovarian suppression) patient with early-stage breast cancer receiving adjuvant systemic therapy;
ANY of the following
- Use to maintain or improve bone mineral density and reduce risk of fractures;
- Use for risk reduction of distant metastasis in patients at high risk (node-positive or high-risk node-negative) per oncology assessment and guideline consideration.

Prostate Cancer - ADT-associated osteoporosis

Patient receiving androgen-deprivation therapy (ADT) with increased fracture risk and intended use is to prevent/treat ADT-associated bone loss;
Documented high fracture risk or declining BMD despite standard care.

Langerhans Cell Histiocytosis

Diagnosis of Langerhans cell histiocytosis with bone disease and zoledronic acid is part of the treatment plan.

Systemic Mastocytosis

Diagnosis of systemic mastocytosis with osteopenia or osteoporosis and zoledronic acid is used to treat bone disease.

Charcot neuroarthropathy (acute) — randomized data suggest zoledronic acid may prolong immobilization time and does not demonstrate clinical benefit; routine pharmacologic treatment is not recommended.

Chronic recurrent multifocal osteomyelitis (CRMO) and other rare inflammatory bone disorders — not established as standard therapy; reports are limited and use is investigational.

Tendon-to-bone healing and use as an adjunct to improve surgical tendon/ligament repair — animal data show decreased pullout strength and reduced stiffness; not supported clinically and considered investigational.

Renal monitoringSerum creatinine should be assessed prior to each treatment and renal function carefully monitored during therapy

FDA safety communicationFDA updated Reclast label noting cases of acute renal failure and recommending screening of patients prior to administration

Albumin-corrected calcium — definition and relevance

cCa formulaAlbumin-corrected calcium (cCa) in mg/dL = measured Ca (mg/dL) + 0.8 × (4.0 g/dL - patient albumin [g/dL])

Use in hypercalcemia of malignancycCa is used to define hypercalcemia of malignancy and guide oncology dosing decisions

Documentation recommendationFor hypercalcemia of malignancy, document albumin-corrected calcium and prior therapies before administration

Hypercalcemia of malignancy threshold (cCa >= 12 mg/dL) for 4 mg dosing

Hypercalcemia of malignancy thresholdAlbumin-corrected serum calcium (cCa) ≥ 12 mg/dL [3.0 mmol/L] defines hypercalcemia of malignancy for 4 mg dosing

Maximum recommended oncology doseMaximum recommended dose in hypercalcemia of malignancy is 4 mg as a single IV infusion over ≥15 minutes

Retreatment interval guidanceRetreatment with 4 mg may be considered if calcium does not normalize; minimum 7 days recommended before retreatment

Renal function cutoff for Reclast (contraindication CrCl < 35 mL/min)

Reclast renal cutoff (contraindication)Zoledronic acid 5 mg (Reclast) is contraindicated in patients with creatinine clearance < 35 mL/min

Evidence of acute renal impairmentUse is contraindicated in patients with evidence of acute renal impairment; cases of acute renal failure requiring dialysis have been reported

Pre-infusion screeningScreen and assess renal function prior to administering Reclast as recommended in label and FDA communication

Corrected serum calcium numeric representation (cCa)

Corrected serum calcium (abbreviation)Albumin-corrected calcium is represented as cCa

UnitsReported in mg/dL (also shown as 3.0 mmol/L for equivalence)

Clinical usecCa used to define hypercalcemia of malignancy and to guide dosing and retreatment decisions

Albumin-corrected calcium (cCa) formula and hypercalcemia definition

cCa calculation (numeric)cCa (mg/dL) = Ca (mg/dL) + 0.8 × (4.0 g/dL - patient albumin [g/dL])

Hypercalcemia numeric thresholdHypercalcemia of malignancy defined using cCa ≥ 12 mg/dL (3.0 mmol/L)

Reporting noteEnsure albumin and total calcium measured in same units to calculate cCa accurately

Paget's disease alkaline phosphatase criterion (>=2x ULN)

Paget's alkaline phosphatase criterionTreatment indicated for Paget disease with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the age-specific normal reference range

Alternative indications for Paget's treatmentAlso indicated for symptomatic disease or patients at risk for complications to induce remission

Administration detailSingle 5 mg IV infusion over ~15 minutes with calcium and vitamin D repletion

Osteoporosis therapy duration consideration (3–5 years discontinuation guidance)

Duration re-evaluation guidanceConsider periodic re-evaluation of continued bisphosphonate therapy and consider drug discontinuation after 3 to 5 years in low-risk patients

Trial duration contextPivotal Reclast osteoporosis data are 3 years in duration (HORIZON trial) informing benefit assessment

Clinical follow-upPatients who discontinue should have fracture risk re-evaluated periodically

WHO osteoporosis threshold (T-score <= -2.5)

WHO osteoporosis thresholdT-score less than or equal to -2.5 defines osteoporosis

Measurement sitesWHO definition applies to BMD at spine, hip, or forearm

Relation to coverage criteriaReclast (5 mg) initial approval criteria reference WHO T-score for treatment eligibility

Postmenopausal = ≥12 months amenorrhea or biochemical confirmation when required (women ≤60 with prior hysterectomy: LH/FSH/estradiol in postmenopausal range).
For adjuvant bisphosphonate requests, record whether therapy is intended for bone density maintenance, fracture risk reduction, or distant metastasis risk reduction.

Prior Authorization

Prior authorization recommended for off‑label or specialty uses

Prior authorization recommended for off‑label, investigational, or specialty uses beyond core FDA or compendial oncology indications. Requests for uses listed as experimental/investigational (e.g., Charcot neuroarthropathy, osteogenesis imperfecta pediatric off‑label, ankylosing spondylitis) should include supporting peer‑reviewed evidence and rationale; absence of adequate evidence may lead to denial.

Concurrent use of multiple ZA formulations or another bisphosphonate is considered experimental — provide justification if requested.
Refer to the CPB list of experimental/unproven indications when submitting requests.

Prior Authorization

Indication and duration justification

Authorization must justify indication and intended duration of therapy. For osteoporosis and glucocorticoid‑associated osteoporosis include numeric criteria (history of fragility fracture, pretreatment T‑score ≤ −2.5, or osteopenia with high FRAX probability). For Paget’s disease document alkaline phosphatase thresholds and re‑treatment rationale. For hypercalcemia of malignancy provide corrected serum calcium and prior therapies.

Osteoporosis: include BMD (T‑score), fracture history, and FRAX when applicable.
Glucocorticoid‑associated osteoporosis: document prednisone‑equivalent dose (≥2.5 mg/day for ≥3 months per policy) and planned duration; note FDA language requiring expected glucocorticoid use ≥12 months for Reclast approval context.
Hypercalcemia: provide albumin‑corrected calcium value (cCa ≥12 mg/dL), prior interventions, and renal function.

Documentation Required

Glucocorticoid‑associated osteoporosis (approval context)

Reclast (zoledronic acid 5 mg) approval context: indicate if request is for treatment or prevention of osteoporosis including glucocorticoid‑induced osteoporosis. For steroid‑induced osteoporosis cite the FDA approval context (expected glucocorticoid use for ≥12 months) and supporting trial data when relevant.

Document planned infusion schedule (annual for treatment; every 2 years permitted for prevention per label) and concurrent calcium/vitamin D supplementation.
For glucocorticoid cases, document current/planned steroid dose and expected duration.

Note

Prior authorization — plan verification

Prior authorization: none stated in some policy chunks, but providers must also refer to plan provisions. The CPB describes clinical rules; actual PA requirements depend on the member’s benefit plan. Verify plan‑level PA rules and the Clinical Policy Bulletin for implementation.

Clinical Policy Bulletins are partial descriptions of plan benefits and do not guarantee coverage; check contract language.
Contact plan administration or use the payer portal to confirm if PA is required for the specific member/plan.

Denial Risk

Evidence‑supported vs limited/experimental indications

Use of zoledronic acid should be limited to indications with evidence of benefit. Evidence‑supported indications include hypercalcemia of malignancy, bone metastases/multiple myeloma for prevention of SREs, and approved osteoporosis indications. Indications with limited, conflicting, or negative evidence (e.g., routine adjuvant use in early breast cancer per some trials, Charcot neuroarthropathy) require careful documentation of rationale and anticipated benefit.

For adjuvant breast cancer, record menopausal status and risk stratification — benefit in adjuvant bisphosphonate trials is largely in postmenopausal women.
Charcot neuroarthropathy: trials suggest lack of benefit or possible harm — routine use is not recommended.

Documentation Required

Pre‑ and post‑infusion patient preparation

Pre‑ and post‑infusion patient preparation must be documented. Obtain baseline renal function (serum creatinine/CrCl) prior to each dose, ensure adequate hydration (especially in hypercalcemia and Paget’s patients), and confirm calcium and vitamin D repletion to reduce hypocalcemia risk. Dental examination and preventive dentistry should be completed prior to therapy when used for cancer‑related bone disease.

Do not administer Reclast if CrCl <35 mL/min or with acute renal impairment — document latest serum creatinine/CrCl.
For Paget’s disease: document hydration plan, orders for calcium 1500 mg elemental and vitamin D 800 IU daily, and patient counseling on hypocalcemia symptoms.

Documentation Required

Therapy duration and re‑evaluation

Therapy duration and re‑evaluation: periodic reassessment of continued therapy is required. For postmenopausal osteoporosis consider discontinuation for low‑risk patients after 3–5 years and re‑evaluate fracture risk; for oncology and hypercalcemia indications, follow disease response and standard oncology intervals.

Document clinical benefit (disease stability/improvement) for continuation requests.
For Paget’s and hypercalcemia, document biochemical response (e.g., alkaline phosphatase normalization, corrected calcium) to support re‑treatment.

Denial Risk

Concurrent use with other bisphosphonates

Concurrent use of zoledronic acid 4 mg with zoledronic acid 5 mg, or concurrent use of another IV bisphosphonate with ZA, is considered experimental/investigational and is not recommended. If such therapy is requested, include clinical justification and supporting evidence.

Policy lists concurrent use with other ZA formulations or another bisphosphonate as investigational.
PA requests for overlapping bisphosphonate regimens will be subject to review and possible denial.

Step Therapy

Agent selection guidance and step therapy considerations

Agent selection guidance: the policy does not mandate step therapy between agents. Selection between zoledronic acid and alternatives (e.g., pamidronate, denosumab) should be clinically justified. Document prior trials, contraindications, or intolerance to alternatives when relevant.

Where relevant, document trial or contraindication to alternative IV bisphosphonate (step therapy considerations vs pamidronate) — also note comparative effectiveness limitations.
For ADT or other oncology prevention settings, note whether denosumab vs ZA selection is based on clinical factors or cost.

Documentation Required

Prior bisphosphonate exposure

Prior bisphosphonate exposure: include history of prior IV or oral bisphosphonate use (e.g., prior pamidronate in pediatric/OI cases) as this may inform dosing decisions and safety monitoring.

For pediatric OI or switch from pamidronate to ZA, document prior dosing history and response.
If prior serious bisphosphonate adverse effects occurred (e.g., osteonecrosis of the jaw), provide risk‑benefit discussion.

Note

Comparative effectiveness context

Comparative effectiveness context: limited head‑to‑head data exist for some indications. When choosing ZA over alternatives, document the comparative rationale (efficacy, dosing frequency, infusion time, renal considerations, and trial data) to support medical necessity.

Hypercalcemia trials show higher response rates and faster infusion time for ZA vs pamidronate — document if this influenced agent choice.
For multiple myeloma and bone metastases, note that ZA and pamidronate have similar effectiveness; denosumab may be superior in some advanced settings.

Step Therapy

Step therapy — none stated in policy summaries

Step therapy: none explicitly required by the evidence summaries in this section, but local plan policies may impose step edits. Check member benefit and PA systems for any plan‑level step therapy rules before submitting.

If plan-level step therapy is present, document completion of required trials or provide clinical rationale for bypassing steps.

Documentation Required

Documentation requirements and FRAX guidance

Documentation and supplemental guidance: ensure PA submissions include BMD measurements, fracture outcomes, laboratory values (e.g., serum creatinine, albumin, corrected calcium, alkaline phosphatase), FRAX calculation when applicable, supplement prescriptions (calcium/vitamin D), dental exam documentation for oncology bone‑modifying therapy, and policy review dates for auditability.

FRAX guidance: high FRAX = 10‑year major osteoporotic fracture risk ≥20% or hip fracture risk ≥3%; adjust score multipliers for higher steroid doses as specified.
Include policy history and review dates (effective 2002‑03‑12; last review 02/01/2024; next review 12/12/2024) for reference in complex cases.

Note

Clinical Policy Bulletin — scope and verification

Clinical Policy Bulletins and scope: CPBs are partial descriptions of plan benefits and do not guarantee coverage. Treating providers are responsible for clinical decisions; verify member benefit terms and use the CPB to support but not replace plan‑level determinations.

CPB updates may change criteria — rely on the current published CPB and payer portal for the operative rules.
Contact payer if there is discrepancy between CPB language and contract terms.

The policy identifies several investigational or limited‑evidence indications, including prevention of radiation‑related insufficiency fractures/AVN (very low‑certainty trial data), spinal cord injury‑related osteoporosis (low to moderate quality evidence for BMD effects but insufficient fracture data), and peri‑prosthetic BMD preservation after total hip arthroplasty (small RCTs/meta‑analysis showing peri‑prosthetic BMD benefit). These summaries highlight evidence limitations and the need for further prospective trials.

Clinical usecCa is required documentation for hypercalcemia of malignancy and for oncology dosing decisions

Albumin-corrected calcium (cCa) formula (duplicate location for oncology dosing relevance)

cCa formula (oncology relevance)cCa in mg/dL = Ca in mg/dL + 0.8 × (4.0 g/dL - patient albumin [g/dL])

Oncology dose thresholdFor hypercalcemia of malignancy, cCa ≥ 12 mg/dL indicates use of 4 mg zoledronic acid; serum creatinine must be assessed prior to each treatment

Retreatment guidanceMinimum 7 days before retreatment to allow full response to initial 4 mg dose

SRE definition — skeletal-related events explained

SRE definitionSkeletal-related events are clinical complications from bone metastases such as fracture, spinal cord compression, or need for radiation or surgery to bone

Clinical contextBisphosphonates including zoledronic acid reduce risk of SREs in patients with bone metastases

Indication linkageZA is approved/used as first-line for multiple myeloma and bone metastases from solid tumors to prevent SREs

Adjuvant bisphosphonate use (postmenopausal) — definition/context

Adjuvant bisphosphonate contextAdjuvant ZA may be considered in postmenopausal breast cancer patients receiving adjuvant systemic therapy to reduce bone recurrence and possibly improve survival

Benefit limitationMeta-analyses show definite benefit primarily in women who were postmenopausal when treatment began

Guideline recommendationASCO/CCO guidelines suggest considering ZA (4 mg every 6 months) as adjuvant therapy for postmenopausal patients deemed candidates for adjuvant systemic therapy

Albumin-corrected calcium (cCa) formula reiterated

Repeated cCa formula referencecCa (mg/dL) = Ca (mg/dL) + 0.8 × (4.0 g/dL - patient albumin [g/dL])

Clinical roleUsed to determine hypercalcemia of malignancy and guide dosing (4 mg) and retreatment intervals

Documentation notePolicy recommends documenting albumin-corrected calcium and prior therapies for hypercalcemia requests

Reclast (zoledronic acid) — description of 5-mg formulation and administration

Reclast 5-mg descriptionReclast (zoledronic acid) is available as a 5 mg/100 mL ready-to-infuse solution administered IV over ~15 minutes

Indications for 5 mg5 mg formulation approved for Paget disease and osteoporosis (treatment/prevention) per FDA-labeled indications

Dosing contrast5 mg (yearly) used for osteoporosis/Paget's versus 4 mg (more frequent) used in oncology indications

Osteoporosis (WHO definition reiterated)

WHO osteoporosis threshold reiteratedOsteoporosis defined as BMD T-score ≤ -2.5 at spine, hip, or forearm

Osteopenia definitionT-score between -2.5 and -1.0 constitutes osteopenia

Policy linkageThese definitions underpin eligibility criteria for Reclast 5 mg in the policy

Radiation-related bone complications definitions (insufficiency fractures, AVN)

Radiation-related bone complication typesIncludes insufficiency fractures (fractures from normal stress on bone weakened by radiotherapy) and avascular necrosis (AVN) due to radiotherapy-related vascular compromise

Evidence statusCurrent evidence for bisphosphonates to prevent these complications is very low certainty; no routine recommendation

Research recommendationProspective trials starting at radiotherapy initiation and continuing 12–24 months are needed

High FRAX fracture probability definition

High FRAX definitionHigh FRAX fracture probability: 10-year major osteoporotic fracture risk ≥ 20% or hip fracture risk ≥ 3%

Use of multipliersMultiply major fracture probability by 1.15 and hip fracture probability by 1.2 if glucocorticoids >7.5 mg/day (prednisone equivalent)

Clinical applicationHigh FRAX thresholds inform treatment decisions for osteopenic patients and glucocorticoid-exposed patients in the policy

FDA safety communication reference noted in definitions

FDA safety communication notedFDA issued a drug safety communication (Sept 1, 2011) updating Reclast label with a contraindication and warning for kidney impairment

Implication for screeningProviders should screen patients for renal risk prior to administration and adhere to label monitoring recommendations

ReferenceFDA safety communication referenced in policy references and background

Policy underwent most recent review on 2024-02-01 (Last review).

2024-12-12scheduled_next_review

Next scheduled policy review date is 2024-12-12.

The background and references note the FDA drug safety communication concerning zoledronic acid (Reclast) with an updated contraindication and warning related to kidney impairment; this communication and the cited references are included in the policy reference list for clinician review.